Remove Medical Remove Pharmacology Remove Prescription Remove Side effects
article thumbnail

Cala® Launches The Cala kIQ™ System, Offering Meaningful Tremor Relief for Patients With Essential Tremor and Now Parkinson’s Disease

Legacy MEDSearch

Treatment options for these conditions have historically been medications or, in more severe cases – surgery. The Cala kIQ System with TAPS therapy offers a non-invasive, non-pharmacologic solution with minimal side effects. Cala is committed to providing patients expanded access to Cala TAPS therapy.

article thumbnail

How NLP Helps Life Sciences Companies Unlock Insights from Drug Labels

PM360

Drug labels hold value for life sciences companies because they are rich, extensive documents that can be used across labeling, regulatory, safety, and medical affairs. Typically, a drug label refers to any information provided with prescription drugs, as requested by regulators such as the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to Get into Pharmaceutical Sales

Rep-Lite

Pharmaceutical Sales refers to selling prescription and over-the-counter (OTC) medications, medical devices, and other healthcare products to healthcare professionals, or medical providers such as doctors, pharmacists, and hospitals. What is Pharmaceutical Sales? Sales experience is highly valued.

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

The company is aiming to enrol the first patient in the ALETTA Phase III trial in Q1 or Q2 of 2023, says Dr. Jan van der Mooren, Freya’s chief medical officer (CMO). Overall, side effects serve as a more significant barrier in this condition than elsewhere because the condition is not life-threatening, says Ben-Zion.